Skip to main content

Table 2 Circulatory hematologic findings

From: Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients—A randomized, open-label, controlled phase II clinical trial

Variables

Cell-treated group (n = 14)

Control group (n = 14)

p value‡

Baseline prior to G-CSF treatment

 Red blood cells (RBC) (× 106)

4.98 ± 0.60

4.49 ± 0.56

0.036

 White blood cells (WBC) (× 103)

8.7 ± 2.2

8.9 ± 3.8

0.866

 Hemoglobin (g/dL)

14.6 ± 1.4

13.3 ± 1.7

0.033

 Platelet (× 103/µL)

237.6 ± 52.3

270.9 ± 134.9

0.398

 Segment (%)

72.8 ± 9.4

69.9 ± 8.3

0.395

 Lymphocyte (%)

18.9 ± 8.4

19.6 ± 6.6

0.804

Compared prior to & after G-CSF treated*

Baseline†

After G-CSF treated†

 

 Red blood cells (× 106)

4.98 ± 0.60

4.58 ± 0.57

 < 0.001

 White blood cells (× 103)

8.7 ± 2.2

49.6 ± 12.1

0.005

 Hemoglobin (g/dL)

14.6 ± 1.4

13.5 ± 1.2

 < 0.001

 Platelet (× 103/µL)

237.6 ± 52.3

228.4 ± 67.9

0.068

 Segment (SEG) (%)

72.8 ± 9.4

81.8 ± 4.4

0.408

 Lymphocyte (LYM) (%)

18.9 ± 8.4

7.0 ± 2.7

0.553

 HPCs (× 103/µL)

92.8 ± 208.4

  1. *Indicated granulocyte colony stimulating factor (G-CSF) was only administered to the cell-treated group by subcutaneous administration (5 μg/kg twice a day for 4 days)
  2. Indicated the parameters of prior to and after G-CSF treatment in group 1 patients
  3. HPCs hematopoietic progenitor cells
  4. Indicated by independent t test or t test for paired data